Diclofenac sodium
Brand names: Voltarol, Diclomax, Voltarol Emulgel
Diclofenac sodium is the standard salt of the NSAID diclofenac, available in oral, modified-release, suppository and parenteral forms for pain and inflammation in arthritis, acute musculoskeletal disorders and postoperative pain.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin production to produce anti-inflammatory, analgesic and antipyretic effects.
Prescribing in practice
- Diclofenac is associated with a higher risk of arterial thrombotic events and is contraindicated in ischaemic heart disease, cerebrovascular disease, peripheral arterial disease and heart failure (MHRA); restrict to the lowest effective dose for the shortest time.
- Provide gastroprotection in those at gastrointestinal risk and avoid concurrent use of other NSAIDs.
- Use caution in renal impairment, hypertension, asthma and the elderly, and avoid in the third trimester of pregnancy.
Monitoring
Review blood pressure, renal function and gastrointestinal tolerance during treatment, especially on prolonged courses or in higher-risk patients.
Counselling the patient
- Take with or after food.
- Report black or tarry stools, indigestion that does not settle, or any chest pain or breathlessness.
- Avoid taking other anti-inflammatory painkillers at the same time unless advised.
Evidence & guidelines
Diclofenac sodium is an established NSAID; its efficacy and cardiovascular/gastrointestinal risk profile are documented in MHRA reviews and NICE osteoarthritis and analgesia guidance.
Reference: NICE NG100; NICE CKS NSAIDs; MHRA Drug Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- MELD-Na Score · Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022